NCT03799848View on ClinicalTrials.gov

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

October 18, 2018

Study Completion Date

October 18, 2018

Conditions
Hepatic Impairment
Interventions
DRUG

Vadadustat

Oral tablet

Trial Locations (2)

55114

Prism Clinical Research, Saint Paul

78215

American Research Corporation at the University of Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY

NCT03799848 - A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function | Biotech Hunter | Biotech Hunter